Mark Bradley

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY.

Part of Bureau Veritas SA, Bradley Construction Management LLC is a company that provides construction management services. The company is based in Dallas, TX. The company was founded by Mark Bradley. Mark Bradley has been the CEO since incorporation. Bradley Construction Management was acquired by Bureau Veritas SA on April 22, 2021.